BGLC Fundamental Analysis - BIONEXUS GENE LAB CORP

Name: BIONEXUS GENE LAB CORP (BGLC) Stock
Brand: BIONEXUS GENE LAB CORP
Rating: 3.5 (3 reviews)

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to BGLC. BGLC was compared to 51 industry peers in the Trading Companies & Distributors industry. While BGLC has a great health rating, there are worries on its profitability. BGLC has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

BGLC had negative earnings in the past year.

BGLC had a negative operating cash flow in the past year.

The reported net income has been mixed in the past 5 years: BGLC reported negative net income in multiple years.

The reported operating cash flow has been mixed in the past 5 years: BGLC reported negative operating cash flow in multiple years.

1.2 Ratios

BGLC's Return On Assets of -31.21% is on the low side compared to the rest of the industry. BGLC is outperformed by 88.24% of its industry peers.

BGLC has a Return On Equity of -39.10%. This is amonst the worse of the industry: BGLC underperforms 86.27% of its industry peers.

		Industry Rank	Sector Rank
ROA	-31.21%
ROE	-39.1%
ROIC	N/A

ROA(3y)-14.68%

ROA(5y)-5.08%

ROE(3y)-17.28%

ROE(5y)-5.01%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

BGLC has a worse Gross Margin (14.13%) than 90.20% of its industry peers.

In the last couple of years the Gross Margin of BGLC has declined.

The Profit Margin and Operating Margin are not available for BGLC so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	14.13%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-7.25%

GM growth 5Y-21.73%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

BGLC does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for BGLC has been increased compared to 1 year ago.

Compared to 5 years ago, BGLC has more shares outstanding

BGLC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 2.81 indicates that BGLC is not a great score, but indicates only limited risk for bankruptcy at the moment.

BGLC's Altman-Z score of 2.81 is in line compared to the rest of the industry. BGLC outperforms 56.86% of its industry peers.

BGLC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	2.81

ROIC/WACCN/A

WACC9.37%

2.3 Liquidity

A Current Ratio of 3.63 indicates that BGLC has no problem at all paying its short term obligations.

With an excellent Current ratio value of 3.63, BGLC belongs to the best of the industry, outperforming 84.31% of the companies in the same industry.

BGLC has a Quick Ratio of 2.93. This indicates that BGLC is financially healthy and has no problem in meeting its short term obligations.

BGLC has a Quick ratio of 2.93. This is amongst the best in the industry. BGLC outperforms 90.20% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.63
Quick Ratio	2.93

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for BGLC have decreased strongly by -47.02% in the last year.

BGLC shows a small growth in Revenue. In the last year, the Revenue has grown by 4.01%.

Measured over the past years, BGLC shows a very strong growth in Revenue. The Revenue has been growing by 135.97% on average per year.

EPS 1Y (TTM)-47.02%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-409.09%

Revenue 1Y (TTM)4.01%

Revenue growth 3Y-10.71%

Revenue growth 5Y135.97%

Sales Q2Q%14.45%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

BGLC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

BGLC does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BIONEXUS GENE LAB CORP

NASDAQ:BGLC (11/12/2025, 4:11:34 PM)

After market: 4.71 -0.13 (-2.69%)

4.84

-0.31 (-6.02%)

Chartmill FA Rating

GICS SectorIndustrials

GICS IndustryGroupCapital Goods

GICS IndustryTrading Companies & Distributors

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst Owners0.53%

Inst Owner Change0%

Ins Owners36.67%

Ins Owner Change0%

Market Cap8.71M

Revenue(TTM)9.55M

Net Income(TTM)-2.94M

AnalystsN/A

Price TargetN/A

Short Float %1.63%

Short Ratio0.13

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.91
P/FCF	N/A
P/OCF	N/A
P/B	1.16
P/tB	1.16
EV/EBITDA	N/A

EPS(TTM)-1.63

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-1.84

FCFYN/A

OCF(TTM)-1.71

OCFYN/A

SpS5.31

BVpS4.18

TBVpS4.18

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-31.21%
ROE	-39.1%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	14.13%
FCFM	N/A

ROA(3y)-14.68%

ROA(5y)-5.08%

ROE(3y)-17.28%

ROE(5y)-5.01%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-7.25%

GM growth 5Y-21.73%

F-Score3

Asset Turnover1.01

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	141.18%
Cap/Sales	2.51%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.63
Quick Ratio	2.93
Altman-Z	2.81

F-Score3

WACC9.37%

ROIC/WACCN/A

Cap/Depr(3y)115.08%

Cap/Depr(5y)162.38%

Cap/Sales(3y)1.47%

Cap/Sales(5y)1.62%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-47.02%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-409.09%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)4.01%

Revenue growth 3Y-10.71%

Revenue growth 5Y135.97%

Sales Q2Q%14.45%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-35.14%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-653.33%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-588.89%

OCF growth 3YN/A

OCF growth 5YN/A

BIONEXUS GENE LAB CORP / BGLC FAQ

What is the fundamental rating for BGLC stock?

ChartMill assigns a fundamental rating of 3 / 10 to BGLC.

What is the valuation status for BGLC stock?

ChartMill assigns a valuation rating of 0 / 10 to BIONEXUS GENE LAB CORP (BGLC). This can be considered as Overvalued.

How profitable is BIONEXUS GENE LAB CORP (BGLC) stock?

BIONEXUS GENE LAB CORP (BGLC) has a profitability rating of 1 / 10.

BIONEXUS GENE LAB CORP (BGLC) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

BIONEXUS GENE LAB CORP / BGLC FAQ

What is the fundamental rating for BGLC stock?

What is the valuation status for BGLC stock?

How profitable is BIONEXUS GENE LAB CORP (BGLC) stock?